<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306228</url>
  </required_header>
  <id_info>
    <org_study_id>GRACIA 3</org_study_id>
    <nct_id>NCT00306228</nct_id>
  </id_info>
  <brief_title>Role of Tirofiban and the Paclitaxel Eluting Stent in Postfibrinolysis Angioplasty</brief_title>
  <acronym>GRACIA3</acronym>
  <official_title>A Randomised Trial to Evaluate the Role of Paclitaxel Eluting Stent and Tirofiban to Improve the Results of Facilitated PCI in the Treatment of Acute ST- Segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GRACIA Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Ministry of Health.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Ministry of Science and Innovation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GRACIA Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The conceptual hypothesis of this study is that, in patients with acute myocardial infarction&#xD;
      and ST-segment elevation, the strategy of performing coronary angioplasty of the culprit&#xD;
      artery with paclitaxel eluting stent significantly reduces the rate of restenosis in&#xD;
      comparison with bare stents.&#xD;
&#xD;
      The conceptual hypothesis of this study is that, in patients with acute myocardial infarction&#xD;
      and ST-segment elevation, the strategy of performing coronary stent-angioplasty of the&#xD;
      culprit artery under the protection of tirofiban 120 minutes after fibrinolytic significantly&#xD;
      improves epicardial and myocardial infusion in comparison with the strategy of performing&#xD;
      immediate intravenous thrombolysis (tenecteplase plus enoxaparine) followed by coronary&#xD;
      angiography and adequate revascularization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of this study are: first to determine the efficacy of paclitaxel&#xD;
      eluting stent compared to conventional bare stent in terms of restenosis, and second to&#xD;
      determine the effect of tirofiban administered prior to percutaneous coronary intervention&#xD;
      (PCI) but 120 minutes after thrombolytic on the epicardial and myocardial flow after&#xD;
      mechanical revascularization in patients with STEMI.&#xD;
&#xD;
      Methods: This is a phased 4, 2x2 randomised, open, multicenter, clinical study. Patients will&#xD;
      be randomised 1:1:1:1 to four groups: a) paclitaxel eluting stent with tirofiban, b)&#xD;
      paclitaxel eluting stent without tirofiban, c) bare stent with tirofiban and d) bare stent&#xD;
      without tirofiban. A total of approximately 436 patients, with &lt;12 hours STEMI will be&#xD;
      enrolled. All patients will be initially treated with tenecteplase (TNK) and enoxaparin.&#xD;
      Tirofiban will start 120 minutes after tenecteplase administration in those patients&#xD;
      randomised to tirofiban. Cardiac catheterization will be performed within the first 3-12&#xD;
      hours after the study inclusion and stenting on the culprit artery, with the randomised&#xD;
      paclitaxel or bare stent, will be performed.&#xD;
&#xD;
      The efficacy of these strategies will be measured in terms of: 1) binary restenosis, defined&#xD;
      as &gt;50% diameter stenosis and segment analysis including the stented segment as well as their&#xD;
      margins, 5 mm proximal and distal to the stent at 9-12 months follow-up and, 2) the&#xD;
      assessment of the epicardial and myocardial perfusion (%TIMI 3, CTFC, CFR-CTFC, TMP y DSA-TMP&#xD;
      and the analysis of the normalization of the ST segment at 90 minutes, 3, 6, 12 and 24 hours&#xD;
      after thrombolysis).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to determine the efficacy of paclitaxel eluting stent compared to conventional bare stent in terms of restenosis</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>to determine the effect of tirofiban administered prior to PCI but 120 minutes after thrombolytic on the epicardial and myocardial flow after mechanical revascularization in patients with STEMI</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to determine the safety of paclitaxel eluting stent in terms of rate of complications, and particularly acute and subacute total occlusion.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the interaction of paclitaxel eluting stent and the complicated myocardial infarction lesion in terms of reduction of intimal proliferation as evaluated by quantitative coronary angiography</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the efficacy of paclitaxel eluting stent in different subgroups of patients: diabetics, small vessel (&lt;2.5 mm), long lesion (&gt;15 mm), gender, and tirofiban use.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the efficacy and safety of full dose fibrinolytic therapy plus delayed tirofiban compared to fibrinolytic therapy alone in different subgroups: diabetics and the elderly</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the efficacy of use of tirofiban in relation to time to fibrinolytic therapy and time to mechanical revascularization.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine possible interactions between the paclitaxel eluting stent and tirofiban in terms of restenosis or acute and subacute total occlusion following coronary stenting.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">436</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>bare-metal stent without tirofiban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>implantation of a bare-metal stent with no tirofiban infusion after fibrinolysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bare-metal stent with tirofiban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>implantation of a bare-metal stent with tirofiban infusion after fibrinolysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel-eluting stent without tirofiban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>implantation of a paclitaxel eluting-stent with no tirofiban after fibrinolysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel-eluting stent with tirofiban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>implantation of a paclitaxel eluting-stent with tirofiban infusion after fibrinolysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Postfibrinolysis percutaneous coronary intervention</intervention_name>
    <description>implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis</description>
    <arm_group_label>bare-metal stent without tirofiban</arm_group_label>
    <other_name>Express stents (Boston Scientific, Natick, Massachusetts)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Postfibrinolysis percutaneous coronary intervention</intervention_name>
    <description>implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis</description>
    <arm_group_label>bare-metal stent with tirofiban</arm_group_label>
    <other_name>Express stents (Boston Scientific, Natick, Massachusetts)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Postfibrinolysis percutaneous coronary intervention</intervention_name>
    <description>implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis</description>
    <arm_group_label>paclitaxel-eluting stent without tirofiban</arm_group_label>
    <other_name>TAXUS stents (Boston Scientific)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Postfibrinolysis percutaneous coronary intervention</intervention_name>
    <description>implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis</description>
    <arm_group_label>paclitaxel-eluting stent with tirofiban</arm_group_label>
    <other_name>TAXUS stents (Boston Scientific)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with ST-segment elevation acute myocardial infarction with all of the following&#xD;
        criteria will be eligible for enrollment:&#xD;
&#xD;
          1. Age &gt;18 years.&#xD;
&#xD;
          2. Chest discomfort &gt;30 minutes with no response to nitroglycerin.&#xD;
&#xD;
          3. Time from the onset of symptoms to randomization &lt; 12 hours.&#xD;
&#xD;
          4. ST segment elevation &gt; 1 mm in two or more limb leads or 2 mm in two or more&#xD;
             contiguous precordial leads or non-diagnostic ECG (left bundle branch block or&#xD;
             pacemaker rhythm) with classic symptoms.&#xD;
&#xD;
          5. Killip class &gt; 3.&#xD;
&#xD;
          6. Written informed consent will be obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients presenting with any of the following will not be included in the study.&#xD;
&#xD;
          1. Cardiogenic shock defined as a systolic blood pressure &lt;90 mm Hg without response to&#xD;
             fluid administration or &lt;100 mmHg in patients with supportive treatment and no&#xD;
             bradycardia.&#xD;
&#xD;
          2. Suspected mechanical complications of acute myocardial infarction.&#xD;
&#xD;
          3. Previous CABG.&#xD;
&#xD;
          4. Non-cardiac disease that is likely to jeopardize the planned termination of the study.&#xD;
&#xD;
          5. Woman of childbearing potential unless a negative pregnant test.&#xD;
&#xD;
          6. Active bleeding and recent (within 2 weeks) surgery that contraindicate the use of&#xD;
             heparin, tirofiban, or platelet aggregation inhibitors.&#xD;
&#xD;
          7. Contraindications for thrombolytic use.&#xD;
&#xD;
               -  previous hemorrhagic stroke at any time&#xD;
&#xD;
               -  history of prior non-hemorrhagic cerebrovascular accident within 12 months&#xD;
&#xD;
               -  intracerebral neoplasia&#xD;
&#xD;
               -  active internal bleeding&#xD;
&#xD;
               -  suspected aortic dissection&#xD;
&#xD;
               -  Uncontrolled hypertension &gt;180/110 in several measurements&#xD;
&#xD;
               -  any other known intracerebral pathology not covered in contraindications&#xD;
&#xD;
               -  Current use of anticoagulants or heparin use within 8 hours&#xD;
&#xD;
               -  known bleeding diathesis&#xD;
&#xD;
               -  recent trauma (&lt; 4 weeks), including head trauma or traumatic or prolonged (&gt;10&#xD;
                  minutes) CPR or recent major surgery or biopsy (&lt;8 weeks)&#xD;
&#xD;
               -  noncompressible vascular punctures&#xD;
&#xD;
               -  recent (&lt; 4 weeks) internal bleeding&#xD;
&#xD;
               -  pregnancy&#xD;
&#xD;
               -  active peptic ulcer&#xD;
&#xD;
          8. History of hypersensitivity to aspirin, ticlopidine, clopidogrel, heparin, tirofiban&#xD;
             and stainless steel.&#xD;
&#xD;
          9. Known renal failure, creatinine &gt;2,5 mg/dL.&#xD;
&#xD;
         10. Known impaired hepatic function that contraindicates the use of clopidogrel.&#xD;
&#xD;
         11. Known thrombocytopenia (100.000).&#xD;
&#xD;
         12. Participation in other trial.&#xD;
&#xD;
         13. Known multivessel disease identified as no suitable for revascularization.&#xD;
&#xD;
         14. Known peripheral vascular disease that difficult cardiac catheterization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Fernandez-Aviles, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>ICICOR, Hospital Clínico Universitario Valladolid, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Ciencias del Corazón (ICICOR). Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>March 21, 2006</study_first_submitted>
  <study_first_submitted_qc>March 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2006</study_first_posted>
  <last_update_submitted>September 25, 2009</last_update_submitted>
  <last_update_submitted_qc>September 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Francisco Fernandez Aviles</name_title>
    <organization>Hospital General Universitario Gregorio Maranon</organization>
  </responsible_party>
  <keyword>ST elevation acute myocardial infarction</keyword>
  <keyword>Thrombolysis</keyword>
  <keyword>Early routine percutaneous coronary intervention</keyword>
  <keyword>tirofiban</keyword>
  <keyword>paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

